IZO:CC - Izotropic Moves to Educate New Demographics on Breast CT Engages New Consultants for Investor Relations & Awareness
(TheNewswire)
VANCOUVER, BC - TheNewswire - April 18, 2022 - Izotropic Corporation (“ Izotropic ” orthe “ Company ”) (CSE: IZO ) (CNSX: IZO.CN ) (OTC: IZOZF ) (FSE: 1R3 ), a companycommercializing a dedicated breast CT (computed tomography) imagingplatform, IzoView, for the more accurate detection and diagnosis ofbreast cancers, announces it has partnered withnew consultants for investor awareness and investor relationsservices. In a move to educate new audiences and demographics on theCompany’s value proposition and upcoming catalysts relative topotential investment, the Company has engaged Blaze Capital andWestmount Capital.
Founded by stock market educatorMr. Justin Caron, Blaze Capital has amassed over 40,000 subscribers on , garnering over 4 million video views and over 100 million minutes ofwatch time. In addition to stock market video content, Blaze Capitaloffers investors a place within a stock market community where theycan join the thousands of users active in their investment portal,participate in paid stock-centered chatrooms, and subscribe to theirpaid newsletter for market insights and access to Mr. Caron’s stockportfolio positions. With a well-established audience that continuesto grow, Blaze Capital has recently begun providing investor awarenessservices by partnering with select small-cap Canadian securities companies. BlazeCapital will be presenting Izotropic across itsplatforms by featuring the Company's forthcoming development progressand news flow through a series of 30 YouTube videos and ongoingcoverage with its investor database through its paidnewsletter.
"Looking at Blaze Capital's audience demographics,almost 90% are under the age of 44, and over 30% of their totalaudience are female," said Dr. John McGraw, CEO of Izotropic. “While patients in this age range may notbe regularly imaged for breast cancer, we doknow that the younger a patient is at the onset of breast cancer themore aggressive the cancer typically is, and unfortunately harder tosee on imaging due to higher breast densities associated with youngerwomen. We also know that investors in this age range care greatlyabout socially responsible investing and are investing earlier andmore than previous generations 1 . Ourpartnership with Blaze Capital is one of multiple planned initiativesto bring our message to this powerful younger group of potentialinvestors.”
The agreement terms are for USD 50k with coverageinitiating April 19, 2022, and do not have a final completion date;rather, the agreement length will be dictated by Izotropic’s newsflow over time to generate the specified number of videos spotlightingthe Company’s progress.
To further diversify Izotropic's investor base andreach, the Company has engaged Switzerland-based Westmount Capital toprovide European investor relations services throughout Europe'sleading financial capitals. Westmount Capital will provide Izotropic with exposure and introductions to itsnetwork of high net-worth investors, family offices, institutionalbrokers, analysts and institutional fund managers, and companies andentrepreneurs participating in the MedTech sector across Europe towhich Izotropic will be making individual presentations. They will beassisting with the translation of corporate materials and the planning and preparation for potential European investment conferences . The agreement terms are for CHF 8,000 (Eightthousand Swiss Francs) per month for an initial three-month term withan option to continue on a month-to-month basis and for 200,000 stockoptions which have been granted to the Westmount team at an exerciseprice of $0.65. The stock options are in effect for a one (1) yearterm, with a vesting schedule of 50% after 30 calendar days and 50%after 90 calendar days.
ON BEHALF OF THE BOARD
Dr. John McGraw, CEO
Investor RelationsContact:
James Berard
Email: jberard@izocorp.com
Cell: 778-228-2314
Toll Free: 1-833-IZOCORP ext.1
Media Inquiries Contact:
Jaclyn Thast
Email: jaclyn@izocorp.com
Toll Free: 1-833-IZOCORP ext.3
About Izotropic Corporation
Izotropic Corporation is the only publicly tradedcompany commercializing a dedicated breast CT imaging platform,IzoView, for the more accurate detection and diagnosis of breastcancers. To expedite patient and provider access to IzoView,Izotropic's initial clinical study intends to demonstrate superiorperformance of diagnostic breast CT imaging over diagnosticmammography procedures and will initiate in Q2 2022. In follow-onclinical studies, Izotropic intends to validate platform applications,including breast screening in radiology, treatment planning andmonitoring in surgical oncology, and breast reconstruction and implantmonitoring in plastic and reconstructive surgery.
More information about Izotropic Corporation can befound on its website at izocorp.com and by reviewing itsprofile on SEDAR at sedar.com.
Forward-Looking Statements
This document may contain statements that are"Forward-Looking Statements," which are based upon thecurrent estimates, assumptions, projections, and expectations of theCompany's management, business, and its knowledge of the relevantmarket and economic environment in which it operates. The Company hastried, where possible, to identify such information and statements byusing words such as "anticipate,""believe," "envision," "estimate,""expect," "intend," "may,""plan," "predict," "project,""target," "potential," "will,""would," "could," "should,""continue," "contemplate" and other similarexpressions and derivations thereof in connection with any discussionof future events, trends or prospects or future operating or financialperformance, although not all forward-looking statements contain theseidentifying words. These statements are not guarantees of performanceand involve risks and uncertainties that are difficult to control orpredict, and as such, they may cause future results of the Company'sactivity to differ significantly from the content and implications ofsuch statements. Forward-Looking Statements are pertinent only as ofthe date on which they are made, and the Company undertakes noobligation to update or revise any Forward-Looking Statements toreflect new information or the occurrence of future events orcircumstances unless otherwise required to do so by law. Neither theCompany nor its shareholders, officers, and consultants shall beliable for any action and the results of any action taken by anyperson based on the information contained herein, including withoutlimitation the purchase or sale of Company securities. Nothing in thisdocument should be deemed to be medical or other advice of anykind. All images are for illustrative purposesonly. IzoView is not yet approved for sale.
1 https://fortune.com/2021/11/18/millennials-genz-investing-markets-wealth-transfer/
Copyright (c) 2022 TheNewswire - All rights reserved.